TB-500 Research for Corneal Healing
An evidence-based overview of research examining TB-500 in the context of corneal healing. This page synthesizes findings from peer-reviewed literature.
Research Summary
Ophthalmic RGN-259 contains full-length thymosin beta-4, not TB-500. In a small randomized neurotrophic-keratopathy study, complete healing at four weeks occurred in 6/10 versus 1/8 participants, but the primary comparison did not reach statistical significance (p=0.0656). A separate dry-eye trial also missed its prespecified primary endpoints, despite secondary signals. Neither trial establishes corneal benefit from TB-500.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.